Metformin Protects against LPS-Induced Intestinal Barrier Dysfunction by Activating AMPK Pathway

Area of Science:

• Gastroenterology
• Cellular Biology
• Pharmacology

Background:

• Lipopolysaccharide (LPS) triggers intestinal barrier damage, inflammation, and oxidative stress.
• Metformin is known for energy metabolism regulation and cellular process involvement.
• Intestinal barrier integrity is crucial for gut health.

Purpose of the Study:

• To investigate metformin's protective effects on LPS-induced intestinal barrier damage.
• To elucidate the molecular mechanisms underlying metformin's action.
• To assess metformin's potential therapeutic role in intestinal diseases.

Main Methods:

• Administered LPS to induce intestinal damage in a study model.
• Treated with metformin to observe its effects on barrier function.
• Analyzed tight junction protein expression (ZO-1, occludin, Claudin1).
• Assessed inflammatory markers, oxidative stress (ROS), NF-κB phosphorylation, and Nrf2 pathway activation.
• Investigated the role of AMPK activation in metformin's protective effects.

Main Results:

• LPS decreased tight junction proteins, increased inflammation and oxidative stress.
• Metformin treatment reversed LPS-induced reduction in tight junction proteins.
• Metformin alleviated LPS-induced NF-κB phosphorylation and promoted Nrf2 nuclear translocation.
• Metformin increased antioxidative gene expression (HO-1, NQO-1), reducing ROS.
• Metformin's protective effects were mediated by AMPK activation.

Conclusions:

• Metformin effectively attenuates LPS-induced intestinal barrier damage, inflammation, and oxidative stress.
• Metformin enhances intestinal barrier function by upregulating tight junction proteins via AMPK activation.
• Metformin shows promise as a therapeutic agent for intestinal diseases characterized by barrier dysfunction.